Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placeboIn prespecified exploratory analyses in the overall trial population, treatment with TNX-103
Tenax's medicine didn't work as well as hoped in its big test—it didn't beat a fake pill on the main goal. When a medicine fails an important test like this, it's a sign the company's plan might need to change.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.